HPR157 Repurposed Drugs Launched Under the AMNOG in Germany: Effects on Benefit Assessment and Price Development

Abstract

Authors

SM Sake A Martyniszyn-Eiben E Zavatta M Glüsen I Berger M Schönermark

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×